The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,595 | -11,284 |
| Depreciation and amortization | 16 | 33 |
| Non-cash lease expense | 55 | 116 |
| Non-cash interest expense on convertible promissory note | 0 | 0 |
| Amortization of debt issuance costs | 0 | 0 |
| Stock-based compensation | 999 | 1,846 |
| Common stock issued to consultant for services rendered | 46 | 60 |
| Restricted stock units released to consultant for services rendered | 0 | 29 |
| Change in fair value of warrants | - | 0 |
| Change in fair value of convertible promissory notes | 0 | 0 |
| Change in fair value of warrants | -1,076 | 0 |
| Gain on expiration of warrants | 724 | - |
| Grant receivable | 0 | - |
| Prepaid expenses and other current assets | -766 | -50 |
| Accounts payable | 1,045 | 963 |
| Accrued expenses | -183 | -115 |
| Operating lease liabilities | -50 | -105 |
| Other current liabilities | -182 | 368 |
| Net cash used in operating activities | -3,850 | -8,072 |
| Purchase of equipment | 13 | 46 |
| Net cash used in investing activities | -13 | -46 |
| Drawdown on loan facilities from juvenescence | 0 | 0 |
| Cash and restricted cash acquired in connection with the merger | 0 | 0 |
| Proceeds from the exercise of post-merger warrants by juvenescence | 0 | 0 |
| Proceeds from the exercise of stock options | 8 | 2 |
| Proceeds from issuance of common stock-Juvenescence | 0 | 4,916 |
| Principal repayment on loan facilities to juvenescence | 0 | 0 |
| Principal repayments on finance lease liabilities | 0 | 0 |
| Proceeds from issuance of series a convertible preferred stock, net | 0 | 4,940 |
| Proceeds from issuance of common stock-At The Market Offering Program | 1,523 | 629 |
| Proceeds from 2025 convertible note, net | 4,913 | - |
| Net cash provided by financing activities | 6,444 | 10,487 |
| Effect of foreign currency on cash | -2 | - |
| Net change in cash and cash equivalents | 2,579 | 2,369 |
| Cash and cash equivalents at beginning of period | 3,672 | - |
| Cash and cash equivalents at end of period | 8,620 | - |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)